Summit Therapeutics SMMT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's financing cash flow?
- Summit Therapeutics (SMMT) reported financing cash flow of $3.8M in Q1 2026.
- How has Summit Therapeutics's financing cash flow changed year-over-year?
- Summit Therapeutics's financing cash flow decreased by 50.5% year-over-year, from $7.68M to $3.8M.
- What is the long-term trend for Summit Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Summit Therapeutics's financing cash flow has grown at a 67.8% compound annual growth rate (CAGR), from $77.92M to $617.53M.
- What does financing cash flow mean?
- The net cash impact of all equity and debt-related transactions.
- How do you interpret financing cash flow?
- Positive values indicate the company is raising capital to fund growth or operations, while negative values suggest the company is paying down debt or returning capital to shareholders.
- How does financing cash flow compare across companies?
- Standard across all industries; biotechs typically show positive net financing cash flow due to frequent capital raises.